G-protein-coupled receptors (GPCRs) are seven-transmembrane proteins that mediate most cellular responses to hormones and neurotransmitters. They are the largest group of therapeutic targets for a broad spectrum of diseases. Recent crystal structures of GPCRs 1-5 have revealed structural conservation extending from the orthosteric ligand-binding site in the transmembrane core to the cytoplasmic G-protein-coupling domains. In contrast, the extracellular surface (ECS) of GPCRs is remarkably diverse and is therefore an ideal target for the discovery of subtype-selective drugs. However, little is known about the functional role of the ECS in receptor activation, or about conformational coupling of this surface to the native ligand-binding pocket. Here we use NMR spectroscopy to investigate ligand-specific conformational changes around a central structural feature in the ECS of the b 2 adrenergic receptor: a salt bridge linking extracellular loops 2 and 3. Smallmolecule drugs that bind within the transmembrane core and exhibit different efficacies towards G-protein activation (agonist, neutral antagonist and inverse agonist) also stabilize distinct conformations of the ECS. We thereby demonstrate conformational coupling between the ECS and the orthosteric binding site, showing that drugs targeting this diverse surface could function as allosteric modulators with high subtype selectivity. Moreover, these studies provide a new insight into the dynamic behaviour of GPCRs not addressable by static, inactive-state crystal structures.
G-protein-coupled receptors (GPCRs) are seven-transmembrane proteins that mediate most cellular responses to hormones and neurotransmitters. They are the largest group of therapeutic targets for a broad spectrum of diseases. Recent crystal structures of GPCRs 1-5 have revealed structural conservation extending from the orthosteric ligand-binding site in the transmembrane core to the cytoplasmic G-protein-coupling domains. In contrast, the extracellular surface (ECS) of GPCRs is remarkably diverse and is therefore an ideal target for the discovery of subtype-selective drugs. However, little is known about the functional role of the ECS in receptor activation, or about conformational coupling of this surface to the native ligand-binding pocket. Here we use NMR spectroscopy to investigate ligand-specific conformational changes around a central structural feature in the ECS of the b 2 adrenergic receptor: a salt bridge linking extracellular loops 2 and 3. Smallmolecule drugs that bind within the transmembrane core and exhibit different efficacies towards G-protein activation (agonist, neutral antagonist and inverse agonist) also stabilize distinct conformations of the ECS. We thereby demonstrate conformational coupling between the ECS and the orthosteric binding site, showing that drugs targeting this diverse surface could function as allosteric modulators with high subtype selectivity. Moreover, these studies provide a new insight into the dynamic behaviour of GPCRs not addressable by static, inactive-state crystal structures.
In the ligand-free basal state, GPCRs exist in an equilibrium of conformations 6 . Ligand binding modulates receptor function by stabilizing different intramolecular interactions and establishing a new conformational equilibrium. Activating ligands (agonists) stabilize receptor conformations that increase signalling through G proteins; inhibiting ligands (inverse agonists) stabilize other conformations that decrease the basal, agonist-independent level of signalling (Supplementary Fig. 1 ). When a GPCR is activated, structural changes occur in the cytoplasmic G-protein-coupling domains. These changes have been characterized for several receptors, including rhodopsin 7-10 and the b 2 adrenergic receptor (b 2 AR) [11] [12] [13] . Recent solid-state NMR data show that light activation of rhodopsin also induces conformational changes in extracellular loop (ECL) 2 (ref. 14) . In rhodopsin, ECL2 forms a structured cap over the covalently bound ligand retinal and interacts with transmembrane (TM) segments involved in activation. However, little is known about the effects of diffusible ligand binding on the extracellular domains of other family A GPCRs, in which ECL2 is displaced away from the ligand-binding pocket. Here we show that ligands known to affect cytoplasmic domain conformation differentially also stabilize distinct ECS conformations ( Supplementary Fig. 1 ).
Understanding conformational changes in the ECS of GPCRs may provide new avenues for drug design. Comparison of the crystallographically identified orthosteric binding pockets of b 2 AR and b 1 AR reveals that 15 of 16 amino acids (94%) are identical 1,5 . This observation underscores the challenge of identifying subtype-selective drugs for families containing several closely related receptors (for example adrenergic, serotonin or dopamine receptors) 15 . In contrast, although the backbone structure of the b 2 AR and b 1 AR extracellular domains are similar, 22 of 39 residues (56%) in ECLs 2 and 3 differ. The ECS therefore provides a diverse site for the development of subtype-selective drugs.
Most of the b 2 AR ECS consists of ECL2, connecting TMs 4 and 5, and ECL3, connecting TMs 6 and 7 ( Fig. 1a ) 1,2 . ECL2 forms a twoturn a-helix that is displaced away from the ligand-binding site entrance (Fig. 1b ). Two disulphide bonds stabilize ECL2, one within the loop and one to the end of TM3. A salt bridge formed by Lys 305 7.32 and Asp 192 ECL2 connects ECL3-TM7 to ECL2 (superscripts in this form indicate Ballesteros-Weinstein numbering for conserved GPCR residues) 16 . Carazolol is an inverse agonist that binds in the orthosteric pocket formed by TMs 3, 5, 6 and 7. The only direct interaction between the ECS and carazolol is through an aromatic interaction with Phe 193 ECL2 . Given these specific associations between ECLs, the orthosteric ligand-binding site and TMs involved in activation 17 , we speculated that b 2 AR extracellular domains and the associated salt bridge rearrange on activation.
To monitor the environment around the Lys 305-Asp 192 salt bridge by NMR, we selectively labelled lysine side chains in a modified b 2 AR (b 2 AR365) with carbon-13 by reductive methylation 18 
(Methods, Supplementary Figs 2-4 and Supplementary Table 1):
This approach exploits the sensitivity of methyl groups as NMR probes for the analysis of large protein structure and dynamics 19 . Reductive methylation adds two [ 13 C]methyl groups to the e-NH 2 of lysine side chains and the a-NH 2 at the receptor amino terminus. The [ 13 C]dimethyllysines serve as conformational probes in twodimensional 1 H-13 C correlation NMR experiments. Dimethylation does not alter the positive charge on the lysine residue (equation (1)) and causes little structural perturbation 20 . We observed no significant changes between the crystal structure of a methylated b 2 AR-Fab complex bound to carazolol and that of the non-methylated receptor (Supplementary Fig. 5 and Supplementary Table 2 ). Reductively [ 13 C]methylated b 2 AR ([ 13 C]methyl-b 2 AR) has ligand-binding properties identical to those of unlabelled b 2 AR, and G-protein coupling is unimpaired ( Supplementary Fig. 6 ).
Intense peaks from dimethylamines (dimethyllysines and the dimethyl-amino terminus) are observed in the 1 H-13 C NMR spectrum of [ 13 C]methyl-b 2 AR bound to the inverse agonist carazolol in detergent buffer ( Fig. 2 , dimethylamine region; Supplementary Fig. 7 , full spectral width). We used both heteronuclear single-quantum coherence (HSQC) and saturation transfer differencing (STD)-filtered 1 H-detected heteronuclear multiple-quantum coherence (HMQC) pulse sequences throughout this work; STD-filtered HMQC improved the spectral quality at the expense of longer acquisition times (Supplementary Fig. 8 ).
Several features of the [ 13 C]methyl-b 2 AR NMR spectrum are notable ( Fig. 2a ). The sharpest peak is assigned to the dimethyl-amino terminus on the basis of protease digestion ( Fig. 2b and Supplementary Fig. 9 ). The remaining peaks are assigned to dimethyllysines. The region is dominated by a cluster of overlapping peaks (centred at 1 H chemical shift 2.8 p.p.m.) attributed to solvent-exposed, highly mobile lysines. The intensity of this cluster is decreased by about 50% after the mutation of seven cytoplasmic lysines to arginine ( Fig. 2b and Supplementary Fig. 10 ). Two broad dimethyllysine peaks are shifted upfield in the 1 H dimension ( Fig. 2a , peaks 1 and 2). These peaks represent the two [ 13 C]methyl groups on Lys 305, as determined by mutation of Lys 305 to Arg ( Fig. 2c and Supplementary Fig. 10 ). The fine structure features in peaks 1 and 2 might suggest conformational heterogeneity; however, they are most probably due to relatively low signal-to-noise ratios and subtle baseline distortions.
Lys 305 is the only lysine that forms a salt bridge in the b 2 AR crystal structure, which is consistent with the unique chemical shifts of peaks 1 and 2. The presence of two peaks implies that the two methyl groups on Lys 305 exist in non-equivalent chemical environments [21] [22] [23] . The two peaks merge under conditions of increased temperature and ionic strength, presumably as a result of weakening of the salt bridge ( Supplementary Fig. 11 ). Reduction of the disulphide bonds stabilizing ECL2 in the b 2 AR abolishes the Lys 305 peaks ( Supplementary Fig. 12 ), demonstrating that the salt bridge is sensitive to conformational changes in the ECS. Taken as a whole, these data show that the Lys 305-Asp 192 salt bridge is formed in solution as well as in crystal lattices for carazolol-bound b 2 AR 2,24 . This conclusion is further supported by measurements of 13 C transverse relaxation (T 2 ) times indicating restricted motion of Lys 305 compared with other b 2 AR lysines ( Supplementary Fig. 13 and Supplementary Table 3 ).
The Lys 305 peaks are a probe for conformational changes in the receptor ECS. Both peaks are present in the NMR spectrum of unliganded b 2 AR, indicating that the Lys 305-Asp 192 salt bridge also forms in the basal state ( Fig. 3a ). Two differences are seen relative to the carazolol-bound state (Fig. 3b ). First, peaks 1 and 2 have a larger upfield shift in the 1 H dimension. Second, the 13 C chemical-shift separation between peaks 1 and 2 is increased. These data show that carazolol binding alters the chemical environment around Lys 305, demonstrating a change in the ECS. In contrast with inverse agonists, neutral antagonists (for example alprenolol) do not alter basal receptor activity. As might be predicted on the basis of ligand efficacy, NMR detects no difference in Lys 305 chemical shifts between unliganded and alprenolol-bound b 2 AR (Fig. 3c ).
The inverse agonist-induced conformational change ( Fig. 3 ) probably involves Phe 193 in ECL2 ( Fig. 1b ), which forms a favourable edge-toface interaction with the tricyclic aromatic ring of carazolol in the b 2 AR crystal structure 1 . Nearly identical interactions are observed with other inverse agonists: Phe 193 and timolol in b 2 AR 24 , and the homologous Phe 201 and cyanopindolol in b 1 AR 5 . By contrast, alprenolol has a single aromatic ring that cannot interact strongly with Phe 193 when docked at the carazolol position. Molecular dynamics simulations show that Phe 193 adopts the trans conformation pointing towards TM5 in the presence of carazolol, but it has increased mobility and is able to assume multiple conformations in the alprenolol-bound state ( Supplementary  Fig. 14) . Phe 193 can form close encounters (less than 5 Å ) with the Lys 305 amine when alprenolol is bound. The observed upfield chemical shift change of peaks 1 and 2 in alprenolol-bound receptor relative to carazolol-bound receptor is therefore most probably due to aromatic ring current effects, although we cannot exclude the possibility of other changes in ECS conformation.
Agonists induce ECS conformational changes that differ from those induced by inverse agonists. Adding formoterol, a b 2 AR agonist with nanomolar affinity, attenuates the Lys 305 resonances (Fig. 4a, b ). The effect is titratable ( Supplementary Fig. 15 ) and reverses when formoterol is replaced by carazolol by dialysis ( Fig. 4c ). Attenuation of Lys 305 resonances was also observed with another, structurally distinct high-affinity agonist ( Supplementary Fig. 16 ). These 26 .
On the basis of our NMR results and computational modelling, we propose that the extracellular ends of TMs 6 and 7 move on activation (Fig. 4d ). In brief, formoterol-activated b 2 AR was modelled on the basis of the crystal structure of ligand-free opsin 9 and a relaxed conformation of the highly distorted Pro 288 6.50 -induced kink ( Supplementary Fig. 17 ).
In this active state model, an inward movement at the extracellular end of TM6 permits the known interaction between Asn 293 6.55 and the chiral b-hydroxyl of the agonist 27 . This motion, simultaneous with outward motion at the intracellular end of TM6 towards TM5 (ref. 9), agrees with the activation model derived from engineering GPCRs with metal-ionbinding sites 28, 29 . The TM6 motion necessitates a lateral displacement of TM7 that reorients the Lys 305 7.32 salt bridge in agreement with NMR spectroscopy (Fig. 4) . Inverse agonists may function in part by stabilizing bulky hydrophobic interactions with Phe 193 ECL2 that block the motion of TM6.
Thus, NMR spectroscopy can be used to investigate structural changes in GPCRs, although the isotopic labelling methods employed here are limited to monitoring changes in the environment and dynamics of accessible lysine side chains. We provide direct biophysical evidence for three distinct conformations of the b 2 AR extracellular surface: one for an unliganded receptor or a neutral antagonist, one for an inverse agonist, and one for an agonist (Fig. 4e ). These conformations correspond to distinct functional behaviour. Unliganded and alprenolol-bound b 2 AR are both able to couple to G s , which is consistent with the basal activity of the receptor and the efficacy of alprenolol (neutral antagonist). In contrast, the inverse agonist carazolol prevents receptor-G s coupling. Finally, agonists promote the strongest coupling. Ligands binding to the extracellular surface could therefore Supplementary Fig. 2 ). b, Spectrum of b 2 AR365 with seven cytoplasmic LysRArg mutations (b 2 AR365 D7Lys) and the N terminus removed by TEV proteolysis. c, Spectrum of b 2 AR365 D7Lys plus the Lys 305RArg mutation and the N terminus removed by TEV proteolysis.
modulate receptor function, either by influencing the binding of orthosteric ligands or by direct allosteric modulation of cytoplasmic domain conformation ( Supplementary Fig. 1 ). Although the specific salt bridge used to monitor these conformations may not be present in other GPCRs, it is ideally positioned to monitor ECS conformations in the b 2 AR, and it is likely that our findings about ligand-induced changes in the ECS are relevant for other family A GPCRs.
METHODS SUMMARY
NMR spectroscopy of [ 13 C]methyl-b 2 AR. Human b 2 AR, tagged with an N-terminal Flag-tobacco etch virus (TEV) protease sequence, and truncated after residue Gly 365 (b 2 AR365; Supplementary Fig. 2 ) was expressed in Spodoptera frugiperda (Sf9) insect cells with recombinant baculovirus. Sf9 cell membranes were solubilized with dodecylmaltoside and purified by sequential antibody affinity and alprenolol affinity chromatography, as described previously 3 . 13 Preparation of modified b 2 -adrenergic receptors for NMR. The coding sequence of wild-type human b 2 AR was cloned into the pFastBac1 Sf9 insect cell expression vector (Invitrogen) and modified as described previously 3 . For small-scale expression trials (1 litre or less), recombinant baculovirus was made with the Bac-to-Bac system (Invitrogen). For large NMR and crystallographyscale expressions, the b 2 AR cDNA was subcloned into the pVL1392 transfer vector and recombinant baculovirus was made with the BestBac system (Expression Systems). All cells were cultured in ESF 921 insect cell medium (Expression Systems). b 2 AR365 ( Supplementary Fig. 2 ) was expressed in Sf9 insect cells infected with baculovirus and solubilized in 1% n-dodecyl-b-Dmaltopyranoside (dodecylmaltoside; Anatrace) in accordance with methods described previously 31 . M1 Flag affinity chromatography (Sigma) was used as the initial purification step. Flag-purified receptor was treated with 100 mM tris(2-carboxyethyl)phosphine followed by two additions of 2 mM iodoacetamide (twice, each for 1 h on ice) to alkylate reactive cysteine residues that can cause disulphide aggregation (these and all other reagents were from Sigma unless otherwise noted). Alternatively, b 2 AR365 was labelled with the cysteine-reactive fluorophore monobromobimane before alkylation, to assess ligand-induced conformational changes 32 . Alkylation was quenched by the addition of 5 mM L-cysteine. Functional b 2 AR365 was then selectively purified by alprenolol-Sepharose chromatography 31 . The next preparation steps varied depending on the particular NMR sample being prepared.
METHODS
Preparation of carazolol-bound [ 13 C]methyl-b 2 AR365. b 2 AR365 (purified by alprenolol-Sepharose) was reductively methylated by sequentially adding 10 mM freshly prepared sodium cyanoborohydride, briefly vortex-mixing, and then adding 10 mM 13 C-enriched (99%) formaldehyde (CLM-806-1; Cambridge Isotope Labs). We feel that the order of reagent addition is important. We preferred to first set a reducing environment in solution to avoid protein crosslinking by formaldehyde. The reductive methylation reaction was then allowed to proceed overnight (minimum 8 h) at 4 uC with nutation. A second addition of sodium cyanoborohydride and [ 13 C]formaldehyde was made exactly as before, followed by another 4 h incubation at 4 uC. [ 13 C]Methyl-b 2 AR365 was then dialysed extensively against buffer A plus 1 mM carazolol to remove unreacted methylation reagents and replace alprenolol with carazolol. Reductive methylation destroys the antigenicity of the M1 Flag epitope, so we could not use a second M1 Flag affinity step to concentrate [ 13 C]methylb 2 AR365 to NMR concentrations. The receptor was instead loaded onto Q Sepharose anion-exchange resin equilibrated in buffer B. We estimate the capacity of Q Sepharose to be about 2.5 mg of [ 13 C]methyl-b 2 AR365 per ml of resin. Binding is largely mediated through the acidic Flag epitope (amino-acid sequence DYKDDDDA), because TEV-cleaved b 2 AR365 does not bind tightly to Q Sepharose resin. The column was then washed with three column volumes of buffer C plus 1 mM carazolol, and eluted with buffer D plus 1 mM carazolol. A one-tenth volume of a saturated cholesterol hemisuccinate solution in buffer A was added to the eluate to enhance receptor stability. [ 13 C]methyl-b 2 AR365 was typically eluted at a concentration of about 100 mM as determined by measurement of carazolol fluorescence 33 . N-linked glycosylations were removed by treatment with PNGase F (New England BioLabs; 750 units per mg of b 2 AR365) for 1 h at 22-25 uC. The sample was dialysed extensively against buffer A plus 100 nM carazolol, followed by two dialysis steps against a small volume (about 25 ml) of buffer A prepared in 98% 2 H 2 O (Cambridge Isotope Labs) plus 100 nM carazolol. Receptor was then concentrated to <200 mM with a 100-kDa cutoff Vivaspin concentrator (Vivascience). It is important to wash the concentrator membrane extensively with water, followed by 2 H 2 O, to remove as much glycerol as possible because it can interfere with NMR spectroscopy.
Final NMR samples (about 270 ml) were loaded into Shigemi microtubes susceptibility-matched to 2 H 2 O (Shigemi Inc.) and sealed. Carazolol-bound [ 13 C]methyl-b 2 AR samples remained stable for more than four months with no visible precipitation, degradation of NMR spectral quality, or decrease in bound carazolol fluorescence. This method was used to prepare the samples shown in Fig. 2a and Supplementary Figs 7-9 and 13 . Preparation of unliganded [ 13 C]methyl-b 2 AR365. b 2 AR365 (purified by alprenolol-Sepharose, 2 mM CaCl 2 added) was loaded directly onto M1 resin for a second Flag affinity step. After loading, the column was washed at 10 ml h 21 with six column volumes of buffer E plus 30 mM atenolol. Atenolol is an antagonist with relatively low affinity for the b 2 AR (K d < 1 mM) 34 . This wash step was included to displace the higher-affinity antagonist alprenolol (K d < 1 nM) from b 2 AR365 by competition. The Flag M1 column was then washed extensively with buffer E to remove atenolol and guarantee that all bound ligand was removed. Unliganded b 2 AR365 was then eluted with buffer F plus Flag peptide (100 mg ml 21 ). Glycosylations were removed by treatment with PNGase F as described earlier. Receptor was dialysed against buffer A with a 20-kDa cutoff dialysis cassette (Slide-A-Lyzer; Pierce) to ensure the removal of Flag peptide before [ 13 C]methylation. Flag peptide (amino-acid sequence DYKDDDDK) has three primary amines that can be [ 13 C]methylated and cause undesirable NMR background.
Unliganded b 2 AR365 was reductively methylated (as described earlier), dialysed against buffer A to remove labelling reagents, dialysed against buffer A prepared in 98% 2 H 2 O, and concentrated for NMR as described above. This method was used to prepare the samples shown in Figs 3 and 4 and Supplementary Figs 12 and 15 . Ligand additions to unliganded [ 13 C]methyl-365N NMR samples were made from ligand stocks dissolved in perdeuterated dimethyl d 6 -sulfoxide (DLM-10-10; Cambridge Isotope Labs). (R,R)formoterol was a gift from Sepracor. Preparation of carazolol-bound [ 13 C]methyl-b 2 AR365 mutants for Lys 305 peak assignment. To facilitate the assignment of dimethyllysine peaks 1 and 2 ( Fig. 2a ), we developed a small-scale expression and purification technique that yields an NMR sample of carazolol-bound b 2 AR365 (about 2-3 mg) from 1-2 litres of Sf9 cells. We modified b 2 AR365 to include a carboxy-terminal hexahistidine tag for nickel affinity chromatography 31 . Six histidine codons were added to the b 2 AR365 cDNA between the Gly 365 and STOP codons (b 2 AR365-His).
To maximize the yield of b 2 AR365-His, we added 200 nM carazolol directly to the culture medium at the time of infection with baculovirus. Buffers for all subsequent purification steps also included a minimum of 200 nM carazolol. We have observed that inverse agonists improve cell-surface expression and help to stabilize the receptor during solubilization. However, the affinity of b 2 AR for carazolol (K d , 0.1 nM) is sufficiently high for binding to be essentially irreversible. This precludes the use of alprenolol-Sepharose chromatography as a functional purification step. Instead, b 2 AR365-His was first purified by Flag affinity chromatography. Reactive cysteine residues were alkylated as described above, and the protein was dialysed extensively against buffer A to remove Flag peptide. Reductive methylation was performed as described above. [ 13 C]Methylb 2 AR365-His was then purified by nickel affinity chromatography (Chelating Sepharose Fast Flow; GE Healthcare) as described previously 31 . Final NMR dialysis and concentration were performed as described above. This method was used to prepare the samples shown in Fig. 2b, c and Supplementary Figs 10 and 11. Crystallographic data collection and processing. Crystals of reductively methylated b 2 AR365-Fab5 complex were generated essentially as described in ref. 3 and were isomorphous to the non-methylated receptor-Fab5 complex. Data collection was performed with the 10-mm collimated microfocus beamline 23ID-B of the Advanced Photon Source at Argonne National Laboratory. A data set comprising 316u of oscillation data was obtained from a single crystal (see Supplementary Table 2 ). Because of radiation damage, only 5-10u of data (1u per frame) could be measured before the crystal was translated to a new position. Data were processed with HKL2000 (ref. 35) . Similarly to the previous b 2 AR24/ 365-Fab5 complex data reduction, global post-refinement of the unit-cell parameters was not performed. Rather, the unit-cell parameters were obtained from indexing and refinement from one wedge of data, and were subsequently used for processing the remaining data without unit-cell constant refinement. Structure solution and refinement. The structure of the methylated b 2 AR365-Fab5 complex was solved by initially performing rigid-body refinement in CNS 36 using the unmethylated b 2 AR24/365-Fab5 complex structure (PDB accession code 2R4S) as a single rigid body. This gave R and R free values of 0.358 and 0.348, respectively. Multiple rounds of manual rebuilding, positional refinement, grouped temperature factor refinement and Translation-Libration-Screw (TLS) refinement were performed with the PHENIX package 37 , bringing R and R free values down to 0.233 and 0.274, respectively. As in the previous b 2 AR24/365-Fab5 complex refinement 3 , only those residues that could be unambiguously assigned were included in the final model. In addition to the residues present in the b 2 AR24/365-Fab5 structure (PDB accession code 2R4S), receptor residues 35-36, 91 and 307-310 were included in the methylated b 2 AR365-Fab5 model. The following receptor residues were modelled as alanine because of insufficient electron density to model full side chains: 36, 39, 42, 49, 53, 55, 63, 69, 77, 112, 114, 120, 122, 131, 147, 156, 209, 227, 232, 263, 279, 287, 308, 309, 321, 324, 326 
